Revive Therapeutics Ltd Stock Price, News & Analysis

Revive Therapeutics Ltd. (OTCQB: RVVTF) is advancing its Phase 3 clinical trial for Bucillamine, targeting patients with mild to moderate COVID-19. Approximately 700 subjects have enrolled, with plans to expand into Turkey by mid-February 2022. The study aims to assess Bucillamine's safety and efficacy, emphasizing that no claims are made regarding its ability to cure COVID-19. The enrollment completion is anticipated by Q1 2022. The company is leveraging FDA regulatory incentives for its drug development efforts, including Orphan Drug and Fast Track designations.

Revive Therapeutics Ltd. (OTCQB: RVVTF) reports progress in its Phase 3 clinical trial evaluating Bucillamine for treating mild to moderate COVID-19. Approximately 700 subjects have been screened, and there are no serious safety concerns reported. The company is expanding patient enrollment to Eastern Europe, particularly Turkey, to diversify its clinical population. Completion of enrollment is expected in Q1-2022, and Revive plans to file for Emergency Use Authorization with the FDA based on the trial results. CEO Michael Frank emphasized the importance of a diverse patient demographic amidst the Omicron variant.

Revive Therapeutics Ltd. (OTCQB: RVVTF) is expanding the research of Bucillamine, an oral drug with anti-viral and anti-inflammatory properties, as a treatment for the Omicron variant of COVID-19. Supported by a recent study from UCSF, Bucillamine has shown potential to inhibit SARS-CoV-2 infection, particularly the Delta variant. The company is enhancing its ongoing Phase 3 clinical study by incorporating inflammatory markers alongside viral load testing to evaluate Bucillamine's effectiveness as both an anti-viral and anti-inflammatory agent.

Revive Therapeutics Ltd. (OTCQB: RVVTF) is expanding its research on Bucillamine, an oral medication, as a potential treatment for the Omicron variant of COVID-19. Supported by a recent UCSF study, Bucillamine has shown efficacy against the Delta variant and may reduce lung injury. The ongoing Phase 3 clinical trial will now include inflammatory marker testing to evaluate Bucillamine's anti-inflammatory effects alongside its antiviral properties. CEO Michael Frank emphasized the motivation to further investigate Bucillamine's therapeutic potential in light of emerging variants.

Revive Therapeutics has applied for Orphan Drug Designation from the FDA for Bucillamine to prevent ischemia-reperfusion injury during liver transplantation. There are currently no approved treatments for this condition, which is a major complication following liver transplants. The Orphan Drug Act offers incentives for the development of drugs for rare diseases. Bucillamine shows promise in replenishing thiol groups in glutathione and has potential anti-inflammatory effects. The drug could improve liver transplant outcomes and expand the availability of donor organs.

Revive Therapeutics Ltd. (OTCQB: RVVTF) announced a significant research study revealing the efficacy of thiol drugs, particularly Bucillamine, in inhibiting SARS-CoV-2 infection, especially the Delta variant. The study highlights Bucillamine's potential in treating mild-to-moderate COVID-19 and reducing lung injury. Revive is undertaking a Phase 3 clinical study on oral Bucillamine and developing a reformulated version for severe cases. Funding for the research came from UCSF and the US National Institutes of Health. The company is also focused on multiple therapeutic areas, including psychedelics and cannabinoids.

Revive Therapeutics Ltd. (OTCQB: RVVTF) announced its inclusion in the inaugural launch of AdvisorShares Psychedelics ETF (PSIL), which began trading on September 16, 2021. This ETF focuses on the emerging psychedelics sector, featuring 16 companies involved in biotechnology and life sciences. CEO Michael Frank expressed that this inclusion validates Revive's strategy regarding psilocybin therapies for mental health. Revive is also advancing psilocybin-based therapeutics and is exploring Bucillamine for treating infectious diseases, including COVID-19.

Revive Therapeutics Ltd. (OTCQB: RVVTF) has entered into an exclusive licensing agreement with Puerto Rico Science Technology and Research Trust, encompassing research from Universidad Central del Caribe and St. Jude Children’s Research Hospital. This collaboration focuses on the medicinal mushroom Ganoderma lucidum, recognized for its anticancer properties, especially against aggressive breast cancers. Revive aims to advance towards FDA clinical trials, following successful in vitro studies and the discovery of key compounds like ergosterol peroxide, which shows significant anticancer activity.

Revive Therapeutics Ltd. (CSE: RVV, USA: RVVTF) has announced its common shares will begin trading on the OTCQB Market from June 28, 2021. This U.S. listing aims to enhance awareness and investor reach. CEO Michael Frank emphasized the company's pursuit of FDA EUA approval for Bucillamine in treating COVID-19 and the advancement of psychedelics for mental health therapies. Revive is also focused on cannabinoid therapies for rare inflammatory diseases, alongside its acquisitions and regulatory incentives from the FDA.